COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that a study to be published in the August 2008 edition of the “Journal of Neurosurgery: Spine” demonstrates that Oxycyte® can help reduce damage caused by oxygen shortages in a spinal cord injury model. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier.
